In this new episode of the pharmaphorum podcast, host Nicole Raleigh speaks with James Burt, CEO of Pharmanovia, about the value-added medicines space.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh